FindTrial
Sign In

Early Initiation of Evolocumab in Acute Coronary Syndrome: A Real-World Comparative Study of Lipid Goal Attainment and Inflammatory Modulation

Early Initiation of Evolocumab in Acute Coronary Syndrome: A Real-World Comparative Study of Lipid Goal Attainment and Inflammatory Modulation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600118799
Enrollment
Unknown
Registered
2026-02-11
Start date
2024-01-01
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Interventions

Evolocumab Group:None
Ezetimibe Group:None
Statin Monotherapy Group:None

Sponsors

Shanghai Pudong New Area Gongli Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Aged >= 18 years; 2.Diagnosed with acute coronary syndrome (ACS), including STEMI and NSTEMI; 3.Underwent percutaneous coronary intervention (PCI).

Exclusion criteria

Exclusion criteria: 1.Known hypersensitivity to PCSK9 inhibitors or statins; 2.Prior history of PCSK9 inhibitor use; 3.Severe hepatic or renal insufficiency; 4.Life expectancy < 1 year due to non-cardiovascular comorbidities; 5.Inability to comply with follow-up visits.

Design outcomes

Primary

MeasureTime frame
LDL-C goal attainment rate;—

Secondary

MeasureTime frame
Percentage change in lipid parameters;Changes in hs-CRP levels;Double compliance rate (LDL-C = 50%);—

Countries

China

Contacts

Public ContactJiang Yufeng

Department of Cardiology, Shanghai Gongli Hospital

jyf19960518@163.com+86 137 0166 4653

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 24, 2026